Combined injectable birth control: Difference between revisions
Content deleted Content added
No edit summary |
Cyberbot II (talk | contribs) Rescuing 1 sources, flagging 0 as dead, and archiving 0 sources. #IABot |
||
| Line 29: | Line 29: | ||
==History== |
==History== |
||
{{Globalize|date=March 2013}} |
{{Globalize|date=March 2013}} |
||
* October 5, 2000, [[Pharmacia]] received FDA approval for Lunelle Monthly Contraceptive Injection.<ref name="contrareportFDAAproveLunelle">{{cite journal |
* October 5, 2000, [[Pharmacia]] received FDA approval for Lunelle Monthly Contraceptive Injection.<ref name="contrareportFDAAproveLunelle">{{cite journal|title=FDA Approves Combined Monthly Injectable Contraceptive |journal=Contraception Report |year=2001 |volume=12 |issue=3 |url=http://www.contraceptiononline.org/contrareport/article01.cfm?art=176 |format= |deadurl=yes |archiveurl=https://web.archive.org/20060926040811/http://www.contraceptiononline.org/contrareport/article01.cfm?art=176 |archivedate=September 26, 2006 }}</ref> |
||
* April 2003, Pharmacia acquired by [[Pfizer]] (makers of [[Depo-provera|Depo-Provera (DMPA)]]). |
* April 2003, Pharmacia acquired by [[Pfizer]] (makers of [[Depo-provera|Depo-Provera (DMPA)]]). |
||
* October 2003, Lunelle was discontinued in the U.S. |
* October 2003, Lunelle was discontinued in the U.S. |
||
Revision as of 15:09, 23 January 2016
| Combined Injectable Contraceptive | |
|---|---|
| Background | |
| Type | Hormonal |
| First use | about 1980 |
| Failure rates (first year) | |
| Perfect use | 0-0.2%[1] |
| Typical use | ? |
| Usage | |
| Duration effect | 1 month |
| User reminders | ? |
| Advantages and disadvantages | |
| STI protection | No |
| Benefits | Especially good if poor pill compliance. |
Combined injectable contraceptive (CIC) monthly injection of a progestin and a synthetic estrogen taken to suppress fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle and Cyclo-Provera.
DMPA is a different injectable contraceptive, containing just a progestin, given every three months.
History
 | The examples and perspective in this article may not represent a worldwide view of the subject. (March 2013) |
- October 5, 2000, Pharmacia received FDA approval for Lunelle Monthly Contraceptive Injection.[1]
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-Provera (DMPA)).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]
Side-effects
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]
Formulations
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.[1]
- Cyclofem contains medroxyprogesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
See also
- Concept Foundation
- Extended cycle combined hormonal contraceptive
- Depo-Provera, a Long-acting reversible contraceptive that is injected every 3 months.
- Reproductive Health Supplies Coalition
Footnotes
- ^ a b c d e f "FDA Approves Combined Monthly Injectable Contraceptive". Contraception Report. 12 (3). 2001. Archived from the original on September 26, 2006.
{{cite journal}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |